SAN DIEGO—(BUSINESS WIRE)—Mar. 4, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Barclays Capital Global
Healthcare Conference on Wednesday, March 11, 2009, at 9:30 a.m. Eastern
Time at the Loews Miami Beach Hotel in Miami Beach, Florida.
A live webcast of ACADIA’s presentation will be accessible on the
company’s website, www.acadia-pharm.com,
under the investors section and an archived recording will be available
on the website through March 25, 2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA is focused on developing a
portfolio of its four most advanced product candidates, including
pimavanserin in Phase III for Parkinson’s disease psychosis, a product
candidate in Phase II for chronic pain and a product candidate in Phase
I for glaucoma, both in collaboration with Allergan, and ACP-106 in
IND-track development. All of the product candidates in ACADIA’s
pipeline emanate from discoveries made using its proprietary drug
discovery platform. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor
Relations
Thomas H. Aasen, Vice President and Chief
Financial Officer
858-558-2871